Clinical Trial Update: A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). [Phase 3]

View source ↗

Summary

The document reports the completion of a long-term Phase 3 trial evaluating the safety and efficacy of efgartigimod in adults with primary immune thrombocytopen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Primary Immune Thrombocytopenia | Phase 3 | Status: COMPLETED